Dishman Carbogen Amcis hit an upper circuit limit of 5% at Rs 321.55 at 14:09 IST on BSE after the company said its Switzerland unit received zero observations from the US health regulator.
The announcement was made during trading hours today, 28 September 2017.Meanwhile, the S&P BSE Sensex was up 48.23 points, or 0.15% to 31,208.04.
On the BSE, 1.89 lakh shares were traded in the counter so far, compared with average daily volumes of 1.15 lakh shares in the past one quarter. The stock had hit a high of Rs 321.55 and a low of Rs 291.05 so far during the day.
Dishman Carbogen Amcis said that its wholly-owned subsidiary, Carbogen Amcis AG's manufacturing site in Bubendorf, Switzerland, has successfully completed a routine US Food and Drug Administration (USFDA) inspection. The inspection was concluded without any major or critical observations or Form 483's, thus confirming that no concerns were discovered during the inspection.
Dishman Carbogen Amcis reported net loss of Rs 8.48 crore in Q1 June 2017 as against net loss of Rs 6.84 crore in Q1 June 2016. Net sales rose 10.57% to Rs 92.23 crore in Q1 June 2017 over Q1 June 2016.
Dishman Carbogen Amcis operates as an outsourcing partner for the pharmaceutical industry.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content